Nearly 40% of patients diagnosed with type 2 diabetes imperil their health by stopping their medication within the first year ...

A concerning number of newly diagnosed patients discontinue their medication within a year. Nearly 40% of patients diagnosed ...

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...

A landmark international study involving patients and researchers at St. Joseph’s Health Care London shows automated insulin ...

Mounjaro’s been great,” the comedian said in an Instagram video. “I’m having a really good experience with it and I wanted to ...

The cardiovascular safety of oral semaglutide, a glucagon-like peptide 1 receptor agonist, has been established in persons with type 2 diabetes and high cardiovascular risk. An assessment of the ...

But insulin treatment for type 1 diabetes combined with today’s society have caused obesity rates to increase in those patients – and along with that, the use of GLP-1 drugs. GLP-1 drugs mimic the GLP ...

Novo Nordisk's hopes of heralding a new era of obesity treatment ... stage trial published in December showed the drug helped ...

He is studying methazolamide, a treatment currently used to manage glaucoma, to find out if it can also help treat ...

Common gut bacteria can metabolise some oral medications potentially rendering these important drugs against migraines, depression, type 2 diabetes, and prostate cancer less ...

Nearly 40% of patients diagnosed with type 2 diabetes imperil their health by stopping their medication within the first year, diabetes experts warn.

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...